These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 28507244)

  • 1. Inhibition of Staphylococcus aureus Cell Wall Biosynthesis by Desleucyl-Oritavancin: a Quantitative Peptidoglycan Composition Analysis by Mass Spectrometry.
    Chang JD; Foster EE; Thadani AN; Ramirez AJ; Kim SJ
    J Bacteriol; 2017 Aug; 199(15):. PubMed ID: 28507244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desleucyl-Oritavancin with a Damaged d-Ala-d-Ala Binding Site Inhibits the Transpeptidation Step of Cell-Wall Biosynthesis in Whole Cells of Staphylococcus aureus.
    Kim SJ; Singh M; Sharif S; Schaefer J
    Biochemistry; 2017 Mar; 56(10):1529-1535. PubMed ID: 28221772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vancomycin and oritavancin have different modes of action in Enterococcus faecium.
    Patti GJ; Kim SJ; Yu TY; Dietrich E; Tanaka KS; Parr TR; Far AR; Schaefer J
    J Mol Biol; 2009 Oct; 392(5):1178-91. PubMed ID: 19576226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of d-Ala incorporation into wall teichoic acid in Staphylococcus aureus by desleucyl-oritavancin.
    Chang J; Coffman L; Kim SJ
    Chem Commun (Camb); 2017 May; 53(41):5649-5652. PubMed ID: 28480909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus.
    Kim SJ; Cegelski L; Stueber D; Singh M; Dietrich E; Tanaka KS; Parr TR; Far AR; Schaefer J
    J Mol Biol; 2008 Mar; 377(1):281-93. PubMed ID: 18258256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hidden Mode of Action of Glycopeptide Antibiotics: Inhibition of Wall Teichoic Acid Biosynthesis.
    Singh M; Chang J; Coffman L; Kim SJ
    J Phys Chem B; 2017 Apr; 121(16):3925-3932. PubMed ID: 28368603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.
    Münch D; Engels I; Müller A; Reder-Christ K; Falkenstein-Paul H; Bierbaum G; Grein F; Bendas G; Sahl HG; Schneider T
    Antimicrob Agents Chemother; 2015 Feb; 59(2):772-81. PubMed ID: 25403671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oritavancin: mechanism of action.
    Zhanel GG; Schweizer F; Karlowsky JA
    Clin Infect Dis; 2012 Apr; 54 Suppl 3():S214-9. PubMed ID: 22431851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular dynamics simulations of the secondary-binding site in disaccharide-modified glycopeptide antibiotics.
    Olademehin OP; Shuford KL; Kim SJ
    Sci Rep; 2022 Apr; 12(1):7087. PubMed ID: 35490171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structures of Staphylococcus aureus cell-wall complexes with vancomycin, eremomycin, and chloroeremomycin derivatives by 13C{19F} and 15N{19F} rotational-echo double resonance.
    Kim SJ; Cegelski L; Preobrazhenskaya M; Schaefer J
    Biochemistry; 2006 Apr; 45(16):5235-50. PubMed ID: 16618112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ion-pairing liquid chromatography-tandem mass spectrometry-based quantification of uridine diphosphate-linked intermediates in the Staphylococcus aureus cell wall biosynthesis pathway.
    Vemula H; Bobba S; Putty S; Barbara JE; Gutheil WG
    Anal Biochem; 2014 Nov; 465():12-9. PubMed ID: 25086364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modeling of Gram-positive bacteria peptidoglycan layer, selected glycopeptide antibiotics and vancomycin derivatives modified with sugar moieties.
    Ślusarz R; Szulc M; Madaj J
    Carbohydr Res; 2014 May; 389():154-64. PubMed ID: 24685455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chlorobiphenyl-desleucyl-vancomycin inhibits the transglycosylation process required for peptidoglycan synthesis in bacteria in the absence of dipeptide binding.
    Goldman RC; Baizman ER; Longley CB; Branstrom AA
    FEMS Microbiol Lett; 2000 Feb; 183(2):209-14. PubMed ID: 10675585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and mode of action of hydrophobic derivatives of the glycopeptide antibiotic eremomycin and des-(N-methyl-D-leucyl)eremomycin against glycopeptide-sensitive and -resistant bacteria.
    Printsevskaya SS; Pavlov AY; Olsufyeva EN; Mirchink EP; Isakova EB; Reznikova MI; Goldman RC; Branstrom AA; Baizman ER; Longley CB; Sztaricskai F; Batta G; Preobrazhenskaya MN
    J Med Chem; 2002 Mar; 45(6):1340-7. PubMed ID: 11882003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the peptidoglycan of vancomycin-susceptible Enterococcus faecium.
    Patti GJ; Kim SJ; Schaefer J
    Biochemistry; 2008 Aug; 47(32):8378-85. PubMed ID: 18642854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance.
    Zeng D; Debabov D; Hartsell TL; Cano RJ; Adams S; Schuyler JA; McMillan R; Pace JL
    Cold Spring Harb Perspect Med; 2016 Dec; 6(12):. PubMed ID: 27663982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterial cell wall composition and the influence of antibiotics by cell-wall and whole-cell NMR.
    Romaniuk JA; Cegelski L
    Philos Trans R Soc Lond B Biol Sci; 2015 Oct; 370(1679):. PubMed ID: 26370936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of action of oritavancin and related glycopeptide antibiotics.
    Allen NE; Nicas TI
    FEMS Microbiol Rev; 2003 Jan; 26(5):511-32. PubMed ID: 12586393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics.
    Billot-Klein D; Gutmann L; Bryant D; Bell D; Van Heijenoort J; Grewal J; Shlaes DM
    J Bacteriol; 1996 Aug; 178(15):4696-703. PubMed ID: 8755902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.